According to the European LeukemiaNet (ELN) risk stratification and National Comprehensive Cancer Network guidelines, AML with BCR::ABL1 fusion is categorized as an adverse risk [6, 7]; therefore, patients should consider allo‐HCT if eligible [8]. This evidence concerns the gene ABL1 and acute myeloid leukemia.